Dichloroquinolinol en es it fr

Dichloroquinolinol Brand names, Dichloroquinolinol Analogs

Dichloroquinolinol Brand Names Mixture

  • No information avaliable

Dichloroquinolinol Chemical_Formula


Dichloroquinolinol RX_link


Dichloroquinolinol fda sheet

Dichloroquinolinol msds (material safety sheet)

Dichloroquinolinol MSDS

Dichloroquinolinol Synthesis Reference

No information avaliable

Dichloroquinolinol Molecular Weight

1749.82 g/mol

Dichloroquinolinol Melting Point

No information avaliable

Dichloroquinolinol H2O Solubility


Dichloroquinolinol State


Dichloroquinolinol LogP

No information avaliable

Dichloroquinolinol Dosage Forms

Vials containing colistimethate sodium or pentasodium colistinmethanesulfonate (150 mg colistin base activity) for injection.

Dichloroquinolinol Indication

For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa.

Dichloroquinolinol Pharmacology

Colistimethate is a polymyxin antibiotic agent. Originally, colistimethate sodium was thought to be less toxic than polymyxin B; however, if the drugs are administered at comparable doses, their toxicities may be similar. Polymyxins are cationic polypeptides that disrupt the bacterial cell membrane through a detergentlike mechanism. With the development of less toxic agents, such as extended-spectrum penicillins and cephalosporins, parenteral polymyxin use was largely abandoned, except for the treatment of multidrug-resistant pulmonary infections in patients with cystic fibrosis. More recently, however, the emergence of multidrug-resistant gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii, and the lack of new antimicrobial agents have led to the revived use of the polymyxins.

Dichloroquinolinol Absorption

Very poor absorption from gastrointestinal tract.

Dichloroquinolinol side effects and Toxicity

Oral LD50 in rats is 5450 mg/kg. Overdosage with colistimethate can cause neuromuscular blockade characterized by paresthesia, lethargy, confusion, dizziness, ataxia, nystagmus, disorders of speech and apnea. Respiratory muscle paralysis may lead to apnea, respiratory arrest and death.

Dichloroquinolinol Patient Information

Dichloroquinolinol Organisms Affected

Gram-negative bacilli